title: Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry.
abstract: Between 1982 and 2000, 172 patients with acute myelogenous leukaemia (AML) received haematopoietic stem cell transplants (SCT) from related (n = 132) or unrelated (n = 40) donors at four Austrian transplant centres and their results were reported to the Austrian Stem Cell Transplantation Registry. Conditioning for SCT consisted of cyclophosphamide and total body irradiation in 156 (91%) patients. Graft-versus-host disease (GVHD) prophylaxis was with standard cyclosporine and methotrexate in 95 (55%) patients. Median post-transplant follow-up was 5.6 years (range, 0.2--16.7). Multivariate analysis of transplant-related mortality (TRM) identified four variables associated with a lower risk: disease status of first complete remission (CR) at SCT, patient age of 45 years and younger, transplant performed during or after 1995, and lack of acute GVHD. Variables associated with significantly improved leukaemia-free survival were: bone marrow as the stem cell source, disease status of first CR at SCT, and occurrence of chronic GVHD. In multivariate analysis, transplantation performed during or after 1995, first CR at SCT, occurrence of limited chronic GVHD and lack of acute GVHD grades III to IV were associated with increased overall survival. Based on these analyses, options for the improvement of results obtained with allogeneic SCT in patients with AML could be defined.
authors.affiliation: Department of Medicine I, Bone Marrow Transplantation Unit, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. hildegarde.greinix@akh.wien.ac.at
authors.forename: Hildegard T
authors.initials: HT
authors.lastname: Greinix
authors.forename: David
authors.initials: D
authors.lastname: Nachbaur
authors.forename: Otto
authors.initials: O
authors.lastname: Krieger
authors.forename: Margit
authors.initials: M
authors.lastname: Eibl
authors.forename: Paul
authors.initials: P
authors.lastname: Knöbl
authors.forename: Peter
authors.initials: P
authors.lastname: Kalhs
authors.forename: Dieter
authors.initials: D
authors.lastname: Lutz
authors.forename: Werner
authors.initials: W
authors.lastname: Linkesch
authors.forename: Dietger
authors.initials: D
authors.lastname: Niederwieser
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hinterberger
authors.forename: Klaus
authors.initials: K
authors.lastname: Lechner
authors.forename: Agathe
authors.initials: A
authors.lastname: Rosenmayr
authors.forename: Beate
authors.initials: B
authors.lastname: Gritsch
mesh_terms: D000328:Adult; D000367:Age Factors; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000601:surgery*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D015999:Multivariate Analysis; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D016572:Cyclosporine; D008775:Methylprednisolone; D008727:Methotrexate